Select Bibliography

Filter by any of these (after searching):

AUTHOR ABSTRACT DEADLINES

A meeting abstract must be submitted by the first or corresponding author to the Alliance Publications Coordinator (publications@AllianceNCTN.org) at least two weeks prior to the meeting abstract submission deadline. For detailed information about Alliance Publications guidelines, please refer to the policies, along with the author abstract deadlines.

There are 79 items

Single nucleotide polymorphisms (SNPs) and circulating endothelial cells (CECs) as outcome predictors in recurrent glioblastoma (rGBM) patients (pts) treated with bevacizumab (BEV) and sorafenib (SOR).

Anderson, S. K. , Lafky, J. M. , Carrero, X. W. , Kimlinger, T. K. ... - ASCO - J. Clin. Oncol. - 2011

Abstract - Secondary-not-in-original - Primary - Neuro-Onc - NCCTG-N0776

Validating RNAseq-Signatures of Vorinostat (VOR) Sensitivity and Resistance in Patients with Newly Diagnosed Glioblastoma (GBM) Treated with VOR, Temozolomide and Radiation Therapy From Alliance N0874/ABTC-0902.

Anderson, S. Keith , Miller, C. Ryan , Sarkaria, Jann N. ... - ASCO - J. Clin. Oncol. - 2016

Abstract - Secondary - Primary - Neuro-Onc - N0874 , ABTC-0902

The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme

Ballman, Karla V. , Buckner, Jan C. , Brown, Paul D. ... - - Neuro-oncol - 2007

Manuscript - Primary - Primary - Neuro-Onc - N047D

Alliance A071101: A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) Vaccine Given with Bevacizumab versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma

Bloch, Orin , Shi, Qian , Anderson, S. Keith , Knopp, Michael ... - SNO - Neuro-Oncology - 2017

Abstract - Primary - Primary - Neuro-Onc - A071101

Alliance A071401: Phase II trial of FAK inhibition in meningiomas with somatic NF2 mutations

Brastianos, Priscilla K. , Twohy, Erin L. , Gerstner, Elizabeth R. ... - ASCO - J Clin Oncol - 2020

Abstract - Primary - Primary - Neuro-Onc - A071401

Alliance A071601: Phase II trial of BRAF/MEK inhibition in newly diagnosed papillary craniopharyngiomas

Brastianos, Priscilla K. , Twohy, Erin , Geyer, Susan ... - ASCO - J Clin Oncol - 2021

Abstract - Primary - Primary - Neuro-Onc - A071601

Alliance A071601: Phase II trial of BRAF/MEK inhibition in newly diagnosed papillary craniopharyngiomas

Brastianos, Priscilla K. , Twohy, Erin , Geyer, Susan ... - AANS - J Neurosurg - 2021

Abstract - Primary - Primary - Neuro-Onc - A071601

Alliance A071701: Genomically guided treatment trial in brain metastases

Brastianos, Priscilla , Anders, Carey , Iafrate, John ... - ASCO - J Clin Oncol - 2020

Abstract - No-Endpoint - Trial-Description-Only - Neuro-Onc - A071701

Development of Clinical Precision Medicine Approaches in Meningiomas: Alliance A071401.

Brastianos, Priscilla , Shi, Qian , Santagata, Sandro ... - SNOM - - 2016

Abstract - No-Endpoint - Trial-Description-Only - Neuro-Onc - A071401

Long term outcomes from intergroup NCCTG 86-72-51 (Alliance): Final report of a phase III prospective randomized trial of high dose versus low dose radiation therapy in adults with supratentorial low-grade glioma.

Breen, William G. , Anderson, S. Keith , Carrero, Xiomara W ... - SNO - Neuro-Oncology - 2019

Abstract - Primary - Long-Term-Followup - Neuro-Onc - NCCTG-85-72-51

Final report from Intergroup NCCTG 86-72-51 (Alliance): a phase III randomized clinical trial of high-dose versus low-dose radiation for adult low-grade glioma

Breen, William G , Anderson, S Keith , Carrero, Xiomara W ... - - Neuro-oncology - 2020

Manuscript - Primary - Long-Term-Followup - Neuro-Onc - NCCTG-86-72-51

A phase II trial (N0177) of erlotinib and temozolomide (TMZ) combined with radiation therapy (RT) in glioblastoma multiforme (GBM)

Brown, P. D. , Krishnan, S. , Sarkaria, J. , Wu, W. , Mischel, P. ... - ASCO - J. Clin. Oncol. - 2008

Abstract - Primary - Primary - Neuro-Onc - NCCTG-N0177

Adult patients with supratentorial pilocytic astrocytoma: long-term follow-up of prospective multicenter clinical trial NCCTG-867251 (Alliance)

Brown, Paul D. , Anderson, S. Keith , Carrero, Xiomara W. ... - - Neurooncol Pract - 2015

Manuscript - Primary - Long-Term-Followup - Neuro-Onc - NCCTG-86-72-51

NCCTG N0574 (Alliance): A Phase III Randomized Trial of Whole Brain Radiation Therapy (WBRT) in Addition to Radiosurgery (SRS) in Patients with 1 to 3 Brain Metastases.

Brown, Paul D. , Asher, Anthony L. , Ballman, Karla V. ... - SNO - Neuro Oncol - 2015

Abstract - Primary - Primary - Neuro-Onc - N0574

NCCTG N0574 (Alliance): A Phase III Randomized Trial of Whole Brain Radiation Therapy (WBRT) in Addition to Radiosurgery (SRS) in Patients with 1 to 3 Brain Metastases

Brown, Paul D. , Asher, Anthony L. , Ballman, Karla V. ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Primary - Primary - Neuro-Onc - N0574

N107C/CEC.3 (Alliance/NCIC): Phase III Trial of Post-Surgical Stereotactic Radiosurgery (SRS) Compared with Whole Brain Radiotherapy (WBRT) for Resected Metastatic Brain Disease

Brown, Paul D. , Ballman, Karla V. , Cerhan, Jane H. ... - ASTRO - Int. J. Radiat. Oncol. Biol. Phys. - 2016

Abstract - Primary - Primary - Neuro-Onc - N107C

Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases

Brown, Paul D. , Jaeckle, Kurt , Ballman, Karla V. , Farace, Elana ... - - JAMA - 2016

Manuscript - Primary - Primary - Neuro-Onc - N0574

Phase I/II Trial of Erlotinib and Temozolomide With Radiation Therapy in the Treatment of Newly Diagnosed Glioblastoma Multiforme: North Central Cancer Treatment Group Study N0177

Brown, Paul D. , Krishnan, Sunil , Sarkaria, Jann N. , Wu, Wenting ... - - J Clin Oncol - 2008

Manuscript - Primary - Primary - Neuro-Onc - N0177

Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial

Brown, Paul D , Ballman, Karla V , Cerhan, Jane H , Anderson, S Keith ... - - Lancet Oncol. - 2017

Manuscript - Primary - Primary - Neuro-Onc - N107C

Prognosis in patients with anaplastic oligoastrocytoma is associated with histologic grade.

Buckner, Jan C , O'Fallon, Judith R , Dinapoli, Robert P ... - - J. Neurooncol. - 2007

Manuscript - Primary - Primary - Neuro-Onc - NCCTG-94-72-52

Stereotactic Radiosurgery with or without Whole Brain Radiotherapy for Limited Brain Metastases: A Secondary Analysis of the NCCTG N0574 (Alliance) Randomized Controlled Trial

Churilla, Thomas M. , Ballman, Karla V. , Brown, Paul D. ... - - Int. J. Radiat. Oncol. Biol. Phys. - 2017

Manuscript - Secondary - Primary - Neuro-Onc - N0574

Validation of EORTC Prognostic Factors for Adults with Low-Grade Glioma: a Report Utilizing Intergroup 86-72-511

Daniels, Thomas B. , Brown, Paul D. , Felten, Sara J. , Wu, Wenting ... - - Int J Radiat Oncol Biol Phys - 2011

Manuscript - Secondary-not-in-original - Primary - Neuro-Onc - NCCTG-86-72-51

Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma

Ellingson, Benjamin M , Abrey, Lauren E , Nelson, Sarah J ... - - Neuro-oncology - 2018

Manuscript - Secondary-not-in-original - Primary - Neuro-Onc - N0874

Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma multiforme: a north central cancer treatment group study.

Friday, B. B. , Buckner, J. , Anderson, S. K. , Giannini, C. ... - SNO - 15th Annual Meeting of the Society for Neuro-Oncology (SNO) - 2010

Abstract - Primary - Primary - Neuro-Onc - N0779

Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study

Friday, Bret B. , Anderson, S. Keith , Buckner, Jan , Yu, Chunrong ... - - Neuro Oncol - 2012

Manuscript - Primary - Primary - Neuro-Onc - N0779

NCCTG phase II trial of bevacizumab in combination with sorafenib (BEV/SOR) in recurrent glioblastoma (RGBM).

Galanis, E. , Anderson, S. K. , Lafky, J. M. , Kaufmann, T. J. ... - SNO - Neuro-oncology - 2011

Abstract - Primary - Primary - Neuro-Onc - N0776

Phase II Study of Bevacizumab in Combination with Sorafenib in Recurrent Glioblastoma (N0776): A North Central Cancer Treatment Group Trial

Galanis, E. , Anderson, S. K. , Lafky, J. M. , Uhm, J. , Giannini, C. ... - - Clin. Cancer Res. - 2013

Manuscript - Primary - Primary - Neuro-Onc - NCCTG-N0776

N047B: NCCTG phase II trial of vorinostat (suberoylanilide hydroxamic acid) in recurrent glioblastoma multiforme (GBM)

Galanis, E. , Jaeckle, K. A. , Maurer, M. J. , Reid, J. M. ... - - J. Clin. Oncol. - 2007

Abstract - Primary - Primary - Neuro-Onc - N047B

NCCTG phase II trial of bevacizumab in combination with sorafenib in recurrent GBM.

Galanis, E. , Jaeckle, K. , Anderson, S. , Kaufmann, T. , Uhm, J. ... - ASCO - J. Clin. Oncol. - 2010

Abstract - Primary - Primary - Neuro-Onc - N0776

Vorinostat in glioblastoma multiforme (Gbm): updated results from phase I and II trials provide the rationale for further clinical development.

Galanis, E. , Jaeckle, K. , Buckner, J. , Maurer, M. , Hardwick, J. ... - ESMO - Ann. Oncol. - 2008

Abstract - Primary - Primary - Neuro-Onc - NCCTG-N047B

Phase I/II trial of vorinostat combined with temozolomide (TMZ) and radiation therapy (RT) for newly diagnosed glioblastoma (GBM) (N0874-ABTC0902, Alliance): Final results of the phase I trial

Galanis, E. , Sarkaria, J. , Anderson, K. , Wu, W. , Jaeckle, K. ... - ASCO - J. Clin. Oncol. - 2013

Abstract - Primary - Primary - Neuro-Onc - N0874

Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02

Galanis, Evanthia , Anderson, S Keith , Miller, C Ryan ... - - Neuro-oncology - 2018

Manuscript - Primary - Primary - Neuro-Onc - N0874

Phase I/randomized phase II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma: North Central Cancer Treatment Group N1174 (Alliance)

Galanis, Evanthia , Anderson, S Keith , Twohy, Erin ... - - Neurooncol Adv - 2022

Manuscript - Primary - Primary - Neuro-Onc - N1174

NCCTG N0872 (Alliance): A Randomized Placebo-Controlled Phase II Trial of Bevacizumab Plus Dasatinib in Patients with Recurrent Glioblastoma (GBM)

Galanis, Evanthia , Anderson, S. Keith , Anastasiadis, Panagiotis Z. ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Primary - Primary - Neuro-Onc - N0872

NCCTG N1174: Phase I/Comparative Randomized Phase II Trial of TRC105 plus Bevacizumab versus Bevacizumab in Bevacizumab-Naïve Patients with Recurrent Glioblastoma Multiforme (Alliance)

Galanis, Evanthia , Anderson, S. Keith , Butowski, Nicholas ... - ASCO - J. Clin. Oncol. - 2017

Abstract - Primary - Primary - Neuro-Onc - N1174

Phase II trial of vorinostat (VOR) combined with temozolomide (TMZ) and radiation therapy (RT) for newly diagnosed glioblastoma (GBM) (Alliance N0874/ABTC-0902)

Galanis, Evanthia , Anderson, S. Keith , Miller, C. Ryan ... - ASCO - J. Clin. Oncol. - 2014

Abstract - Primary - Primary - Neuro-Onc - N0874

A Phase I and Randomized Placebo-Controlled Phase II Trial of Bevacizumab plus Dasatinib in Patients with Recurrent Glioblastoma (GBM): Alliance/NCCTG N0872

Galanis, Evanthia , Anderson, S. Keith , Twohy, Erin L. ... - - Cancer - 2019

Manuscript - Primary - Primary - Neuro-Onc - N0872

Phase II Trial of Vorinostat in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study

Galanis, Evanthia , Jaeckle, Kurt A. , Maurer, Matthew J. ... - - J Clin Oncol - 2009

Manuscript - Primary - Primary - Neuro-Onc - N047B

Central Pathology Review by Whole Slide Imaging in Glioblastoma Clinical Trials

Giannini, Caterina , Miller, Ryan , Ligon, Keith , Tollefson, Helen ... - AANP - J Neuropathol Expl Neurol - 2015

Abstract - Secondary-not-in-original - Meta-Analysis - Neuro-Onc - N0872 , N0877

New validated prognostic models and prognostic calculators in patients with low-grade gliomas diagnosed by central pathology review: a pooled analysis of EORTC/RTOG/NCCTG phase III clinical trials

Gorlia, Thierry , Wu, Wenting , Wang, Meihua , Baumert, Brigitta G. ... - - Neuro-oncology - 2013

Manuscript - Secondary - Comprehensive - Neuro-Onc - NCCTG-86-72-51

Local control after resection and adjuvant radiosurgery compared to radiosurgery alone for brain metastasis: Exploratory analysis of Alliance NCCTG N107C

Hansen, Chase C. , Ballman, Karla V. , Anderson, S. Keith ... - ASTRO - Int J Radiation Biol Physics - 2020

Abstract - Secondary-not-in-original - Primary - Neuro-Onc - N107C

Transformation of low grade glioma and correlation with outcome: an NCCTG database analysis.

Jaeckle, K A , Decker, P A , Ballman, K V , Flynn, P J , Giannini, C ... - - J. Neurooncol. - 2011

Manuscript - Secondary-not-in-original - Comprehensive - Neuro-Onc - Comprehensive , NCCTG-85-72-51 , NCCTG-86-03-51 , NCCTG-88-72-02 , NCCTG-88-72-52 , NCCTG-90-72-01 , NCCTG-91-72-01 , NCCTG-92-72-03 , NCCTG-93-72-02 , NCCTG-93-72-52 , NCCTG-88-72-51 , NCCTG-89-72-51 , NCCTG-89-72-52 , NCCTG-91-72-51 , NCCTG-92-72-51 , NCCTG-93-72-51 , NCCTG-95-72-53 , NCCTG-98-72-54 , N997B , NCCTG-84-72-51 , NCCTG-86-72-02 , NCCTG-86-72-53 , N0074 , N0272 , NCCTG-98-72-52 , NCCTG-86-72-51 , NCCTG-98-72-51 , NCCTG-96-72-51

NCCTG N0272: phase II trial of imatinib mesylate; (gleevec; sti571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma: a north central cancer treatment group study.

Jaeckle, K. A. , Anderson, S. K. , Kosel, M. , Sarkaria, J. ... - SNO - Neuro-oncology - 2011

Abstract - Primary - Primary - Neuro-Onc - N0272

NCCTG N0572 phase I/II trial of sorafenib and temsirolimus in patients with recurrent glioblastoma: A North Central Cancer Treatment Group study

Jaeckle, K. A. , Schiff, D. , Anderson, S. K. , Galanis, E. ... - ASCO - J. Clin. Oncol. - 2011

Abstract - Primary - Preliminary - Neuro-Onc - N0572

Correlation of response with survival endpoints in patients with newly diagnosed and recurrent glioblastoma (GBM) treated on prospective North Central Cancer Treatment Group (NCCTG) clinical trials

Jaeckle, K. A. , Wu, W. , Kosel, M. , Flynn, P. J. ... - ASCO - J. Clin. Oncol. - 2008

Abstract - Primary - Primary - Neuro-Onc - N047D

Phase I/II trial of sorafenib and CCI-779 in patients with recurrent glioblastoma (GBM)

Jaeckle, K. , Anderson, K. , Sarkaria, J. , Decker, P. , Buckner, J. ... - ICTT - - 2008

Abstract - Primary - Preliminary - Neuro-Onc - NCCTG-N0572

Results of a phase II trial of vorinostat in patients with recurrent glioblastoma: Evidence of post-treatment histone acetylation in tumor tissue and pharmacokinetic analysis: North Central Cancer Treatment Group (NCCTG) study N047B

Jaeckle, K. , Maurer, M. , Reid, J. , Ames, M. , Giannini, C. ... - TAT - - 2007

Abstract - Primary - Primary - Neuro-Onc - NCCTG-N047B

NCCTG (Alliance) N0572: A phase II trial of sorafenib and temsirolimus in recurrent glioblastoma (GBM) patients who progress following prior RT/temozolomide (TMZ) and VEGF inhibitors (VEGFi)

Jaeckle, K. , Schiff, D. , Anderson, S. , Galanis, E. , Stella, P. ... - ASCO - J. Clin. Oncol. - 2013

Abstract - Primary - Primary - Neuro-Onc - N0572

Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North Central Cancer Treatment Group study N0272 (Alliance/NCCTG)

Jaeckle, Kurt A. , Anderson, S K. , Twohy, Erin L. , Dixon, Jesse G. ... - - J. Neurooncol. - 2019

Manuscript - Primary - Primary - Neuro-Onc - N0272

CODEL: Phase III study of RT alone, RT plus temozolomide, or temozolomide alone for newly diagnosed 1P/19Q codeleted anaplastic oligodendroglioma patients. Updated analysis from the initial study design (NCCTG N0577, Alliance)

Jaeckle, Kurt A. , Ballman, Karla V. , van den Bent, Martin ... - SNO - Neuro-Oncology - 2020

Abstract - Primary - Other - Neuro-Onc - N0577

Correlation of enzyme-inducing anticonvulsant use with outcome of patients with glioblastoma

Jaeckle, Kurt A. , Ballman, Karla , Furth, Alfred ... - - Neurology - 2009

Manuscript - Primary - Primary - Neuro-Onc - N0475

CODEL: phase III study of RT, RT + TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study design

Jaeckle, Kurt A , Ballman, Karla V , van den Bent, Martin ... - - Neuro Oncol - 2020

Manuscript - Primary - Preliminary - Neuro-Onc - N0577

CODEL (Alliance-N0577; EORTC-26081/22086; NRG-1071; NCIC-CEC-2): Phase III randomized study of RT vs. RT+TMZ vs. TMZ for newly diagnosed 1p/19q-codeleted anaplastic glioma. Analysis of patients treated on the original protocol design

Jaeckle, Kurt , Vogelbaum, Michael , Ballman, Karla ... - AAN - Neurology - 2016

Abstract - Primary - Other - Neuro-Onc - N0577

CODEL (Alliance N0577; EORTC 26081/22086 ; NRG 1071; NCIC CEC-2): A Phase III Randomized Intergroup Study for patients (pts) with newly diagnosed 1p/19q codeleted anaplastic glioma. Preliminary analysis of patients treated on the original protocol design with RT vs. RT + concomitant/adjuvant TMZ vs. TMZ alone

Jaeckle, Kurt , Voglebaum, Michael , Ballman, Karla ... - SNO - Neuro Oncol - 2015

Abstract - Primary - Preliminary - Neuro-Onc - N0577

Improved outcome in recurrent glioblastoma (RGBM) patients treated with bevacizumab (BEV) and sorafenib (SOR) is predicted by a greater drop in apparent diffusion coefficient (ADC) on MRI imaging.

Kaufmann, T. J. , Anderson, S. K. , Jaeckle, K. A. , Uhm, J. H. ... - SNO - 16th Annual Scientific Meeting of the Society for Neuro-Oncology in Conjunction with the AANS/CNS Section on Tumors - 2011

Abstract - Secondary-not-in-original - Primary - Neuro-Onc - N0776

Phase I randomized phase II trial of either dasatinib or placebo combined with standard chemoradiotherapy for newly diagnosed glioblastoma multiforme (GBM): Final results of phase I study

Laack, N. N. , Galanis, E. , Leinweber, C. , Buckner, J. C. ... - ASCO - J. Clin. Oncol. - 2012

Abstract - Primary - Preliminary - Neuro-Onc - N0877

Randomized Placebo-Controlled Phase II Study of Dasatinib with Standard Chemo-Radiotherapy for Newly Diagnosed Glioblastoma (GBM), N0877

Laack, Nadia , Galanis, Eva , Anderson, S. Keith , Leinweber, Clinton ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Primary - Primary - Neuro-Onc - N0877

Joint NABTC + NCCTG prognostic factors analysis for high grade recurrent glioma

Lamborn, K. , Wu, W. , Prados, M. , Jaeckle, K. , Chang, S. ... - - J. Clin. Oncol. - 2007

Abstract - Secondary-not-in-original - Comprehensive - Neuro-Onc - N0678

Validation of Single-Item Linear Analog Scale Assessment of Quality of Life in Neuro-Oncology Patients

Locke, Dona E.C. , Decker, Paul A. , Sloan, Jeff A. , Brown, Paul D. ... - - J Pain Symptom Manage - 2007

Manuscript - Secondary-not-in-original - Comprehensive - Neuro-Onc - N0074 , NCCTG-98-72-51 , NCCTG-98-72-52

NCCTG N057K phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: A North Central Cancer Treatment Group trial.

Ma, D. , Galanis, E. , Schiff, D. , Wu, W. , Peller, P. J. ... - ASCO - J. Clin. Oncol. - 2012

Abstract - Primary - Long-Term-Followup - Neuro-Onc - N057K

A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K

Ma, Daniel J. , Galanis, Evanthia , Anderson, S. Keith ... - - Neuro-oncology - 2015

Manuscript - Primary - Long-Term-Followup - Neuro-Onc - N057K

N107C/CEC.3 (Alliance for Clinical Trials in Oncology/Canadian Cancer Trials Group): Phase III Trial of Post-Operative Stereotactic Radiosurgery (SRS) Compared with Whole Brain Radiotherapy (WBRT) for Resected Metastatic Brain Disease: Cognitive function of long-term survivors

Roberge, David , Ballman, Karla V. , Cerhan, Jane H. ... - SNO - Neuro-Oncology - 2017

Abstract - Secondary - Primary - Neuro-Onc - N107C

Phase II trial of two different irinotecan schedules with pharmacokinetic analysis in patients with recurrent glioma: North Central Cancer Treatment Group results

Santisteban, Marta , Buckner, Jan C. , Reid, Joel M. , Wu, Wenting ... - - J Neurooncol - 2009

Manuscript - Primary - Primary - Neuro-Onc - NCCTG-96-72-51

NCCTG phase I trial of Everolimus (RAD001) and Temozolomide (TMZ) in combination with radiation therapy (RT) in newly diagnosed glioblastoma multiforme (GBM) patients (N057K).

Sarkaria, J. N. , Galanis, E. , Peller, P. J. , Brown, P. D. , Wu, W. ... - AACR-NCI-EORTC - Mol Cancer Ther - 2009

Abstract - Primary - Primary - Neuro-Onc - NCCTG-N057K

NCCTG phase I trial of temsirolimus (CCI-779) and temozolomide (TMZ) in combination with radiation therapy (RT) in newly diagnosed glioblastoma multiforme (GBM) patients

Sarkaria, J. N. , Galanis, E. , Wu, W. , Giannini, C. , Jaeckle, K. A. ... - ASCO - J. Clin. Oncol. - 2009

Abstract - Primary - Primary - Neuro-Onc - N027D

Effect of combined therapy with temsirolimus (CCI-779), temozolomide (TMZ), and radiation (RT) in newly diagnosed glioblastoma multiforme (GBM) patients on immune suppression: results from NCCTG N027D

Sarkaria, J. , Galanis, E. , Gustafson, M. , Dietz, A. , Wu, W. ... - ASCO - J. Clin. Oncol. - 2010

Abstract - Primary - Primary - Neuro-Onc - NCCTG-N027D

FLT-PET analysis of early response to everolimus in newly diagnosed glioblastoma patients enrolled on NCCTG N057K

Sarkaria, J. , Peller, P. , Galanis, E. , Jacobson, M. , Wu, W. ... - ASCO - J. Clin. Oncol. - 2011

Abstract - Secondary - Primary - Neuro-Onc - NCCTG-N057K

Combination of temsirolimus (CCI-779) with chemo-radiation in newly diagnosed GBM (NCCTG trial N027D) is associated with increased infectious risks1

Sarkaria, Jann N. , Galanis, Eva , Wu, Wenting , Dietz, Allan B. ... - - Clin Cancer Res - 2010

Manuscript - Primary - Primary - Neuro-Onc - N027D

NCCTG Phase I Trial N057K of Everolimus (RAD001) and Temozolomide in Combination with Radiation Therapy in Newly Diagnosed Glioblastoma Multiforme Patients1

Sarkaria, Jann N. , Galanis, Evanthia , Wu, Wenting ... - - Int J Radiat Oncol Biol Phys - 2011

Manuscript - Primary - Primary - Neuro-Onc - N057K

Feasibility/tolerability results from a phase I/II study of temsirolimus (CCI-779) and sorafenib in recurrent glioblastoma: North Central Cancer Treatment Group (NCCTG) N0572

Schiff, D. , Sarkaria, J. , Decker, P. , Buckner, J. , Galanis, E. ... - SNO - Neuro-oncology - 2009

Abstract - Primary - Preliminary - Neuro-Onc - N0572

Phase I study of temsirolimus (CCI-779) and sorafenib in recurrent glioblastoma: North central cancer treatment group (NCCTG) N0572

Schiff, D. , Sarkaria, J. , Decker, P. , Buckner, J. , Galanis, E. ... - SNO - Neuro-oncology - 2007

Abstract - Primary - Preliminary - Neuro-Onc - N0572

Phase I/II Trial of Temsirolimus and Sorafenib in Treatment of Patients with Recurrent Glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572

Schiff, David , Jaeckle, Kurt A , Anderson, S. Keith ... - - Cancer - 2018

Manuscript - Primary - Primary - Neuro-Onc - N0572

Brain Metastases From Melanoma

Schild, Steven E. , Behl, Deepti , Markovic, Svetomir N. ... - - Am. J. Clin. Oncol. - 2010

Manuscript - Primary - Primary - Neuro-Onc - N0274

Radiation treatment volumes before and after BRAF/MEK therapy in newly diagnosed papillary craniopharyngiomas: A correlative analysis of the Alliance A071601 phase II trial

Shih, Helen A. , Tabrizi, Shervin , Kabat, Brian F. , Twohy, Erin ... - SNO - Neuro-Oncology, Volume 23, Issue Supplement_6, November 2021, Page vi72, - 2021

Abstract - Secondary - Primary - Neuro-Onc - A071601

Optimizing whole brain radiotherapy dose and fractionation: Results from a prospective phase III trial (Alliance)

Trifiletti, Daniel M. , Ballman, Karla V. , Brown, Paul D. ... - ASTRO - International Journal of Radiation Oncology • Biology • Physics - 2019

Abstract - Secondary-not-in-original - Primary - Neuro-Onc - N107C

Optimizing Whole Brain Radiation Therapy Dose and Fractionation: Results From a Prospective Phase 3 Trial (NCCTG N107C [Alliance]/CEC.3).

Trifiletti, Daniel M , Ballman, Karla V , Brown, Paul D ... - - Int. J. Radiat. Oncol. Biol. Phys. - 2020

Manuscript - Secondary-not-in-original - Primary - Neuro-Onc - N107C

Phase II evaluation of gefitinib in patients with newly diagnosed grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group study N0074 1

Uhm, Joon H. , Ballman, Karla V. , Wu, Wenting , Giannini, Caterina ... - - Int. J. Radiat. Oncol. Biol. Phys. - 2011

Manuscript - Primary - Primary - Neuro-Onc - N0074

Relationship between overall survival and progression-free survival for recent NCCTG glioblastoma multiforme trials

Wu, W. , Galanis, E. , Buckner, J. C. , Jaeckle, K. A. ... - ASCO - J. Clin. Oncol. - 2012

Abstract - Secondary-not-in-original - Comprehensive - Neuro-Onc - Comprehensive

Joint NCCTG and NABTC prognostic factors analysis for high-grade recurrent glioma

Wu, Wenting , Lamborn, Kathleen R. , Buckner, Jan C. ... - - Neuro Oncol - 2010

Manuscript - Secondary-not-in-original - Comprehensive - Neuro-Onc - N0678